PATIENTS CALL FOR MEANINGFUL INVOLVEMENT IN EUROPEAN COOPERATION ON HTA

Patients contribute to high quality scientific health technology assessment

IDF Europe  together with 13 European patients' organisations  express concern that patient involvement is not adequately considered in the ongoing negotiations on the Health Technology Assesment (HTA) Regulation. 

The success of this legislation and the quality of HTA at any level cannot be separated from the adequate involvement of patients, in line with other EU legislation on healthcare. That is why we call on negotiators to open up to the possibility of involving patients in the future cooperation on HTA.

Patients and their organisations welcome efforts set out in the EU proposal for a new legislation on health technology assessment (HTA) to adopt high quality methods and standards when assessing health technologies they use for their own treatment. However, patients and their organisations are convinced that changes need to be made to the legislation before it is adopted to guarantee an adequate involvement of patients in all HTA activities (joint consultations, early dialogues, scoping and assessments), which is essential to help HTA assessors determine the relative efficacy and safety of health technologies.

Read the full statement here

The organisation joining HTA statement are: 

  • AE - Alzheimber Europe
  • EATG - European AIDS Treatment Group
  • ECPC - European Cancer Patient Coalition
  • EFA - European Federation of Allergy and Airways Diseases Patients’ Associations
  • EFNA - European Federation of Neurological Associations
  • EHN - European Heart Network
  • EMSP - European Multiple Sclerosis Platform
  • EPF - European Patient Forum
  • EUomo - European Prostate Cancer Coalition
  • IDF Europe - International Diabetes Federation European Region
  • IPOPI - International Patient Organisation for Primary Immunodeficiences
  • MPE - Myeloma Patients Europe
  • EGAN - Patients’ Network for Medical Research and Health
  • EURORDIS - Rare Diseases Europe
Back to publications
© 2019 International Diabetes Federation Disclaimer